Rituximab in chronic lymphocytic leukemia

Advances in Therapy

Volumn 28, Issue 7, 2011, Pages 534-554

  James, Danelle F ^a   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD20; Chronic lymphocyticleukemia; CLL; Monoclonal antibody; Rituxan; Rituximab; Treatment

Indexed keywords

ALEMTUZUMAB; ANTIINFECTIVE AGENT; BENDAMUSTINE; CD20 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETANERCEPT; FC RECEPTOR; FC RECEPTOR IIA; FLUDARABINE; FLUDARABINE PHOSPHATE; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; LENALIDOMIDE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; OXALIPLATIN; PENTOSTATIN; RITUXIMAB; VELTUZUMAB;

B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; CYTOPENIA; DRUG ACTIVITY; DRUG COST; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FEVER; FOLLICULAR LYMPHOMA; HUMAN; HYPOTENSION; HYPOXEMIA; INFECTION; INFUSION REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; VIDARABINE;

EID: 82455167850     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0032-2     Document Type: Review

References (73)

1. Hallek M, Cheson BD, Catovsky D, et al.Guidelines for the diagnosis and treatment ofchronic lymphocytic leukemia: A report from the International Workshop on Chronic LymphocyticLeukemia updating the National CancerInstitute-Working Group 1996 guidelines. Blood.2008;111: 5446-5456.
2. US Food and Drug Administration. FDA approvesrituxan to treat chronic lymphocytic leukemia.Available at: Http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm201069.htm.Accessed May 18, 2011.
3. Maloney DG, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol.2002;29(Suppl. 2): 2-9. (Pubitemid 34171789)
4. Smith MR. Rituximab (monoclonal anti-CD20antibody): Mechanisms of action and resistance.Oncogene. 2003;22: 7359-7368.
5. Robak T, Dmoszynska A, Solal-Celigny P, et al.Rituximab plus fludarabine and cyclophosphamideprolongs progression-free survival comparedwith fludarabine and cyclophosphamide alone inpreviously treated chronic lymphocytic leukemia.J Clin Oncol. 2010;28: 1756-1765.
6. Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantlecell lymphoma cells in intravenous andsubcutaneous SCID mouse models. J Immunol.2007;179: 4263-4271.
7. Williams ME, Densmore JJ, Pawluczkowycz AW,et al. Thrice-weekly low-dose rituximab decreasesCD20 loss via shaving and promotes enhancedtargeting in chronic lymphocytic leukemia.J Immunol. 2006;177: 7435-7443. (Pubitemid 44715114)
8. Aue G, Lindorfer MA, Beum PV, et al. Fractionatedsubcutaneous rituximab is well-tolerated andpreserves CD20 expression on tumor cells inpatients with chronic lymphocytic leukemia.Haematologica. 2010;95: 329-332.
9. Berinstein NL, Grillo-Lopez AJ, White CA, Bence,et al. Association of serum rituximab (IDECC2B8)concentration and anti-tumor responsein the treatment of recurrent low-grade orfollicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9: 995-1001. (Pubitemid 28496709)
10. Regazzi MB, Iacona I, Avanzini MA, et al.Pharmacokinetic behavior of rituximab: A studyof different schedules of administration forheterogeneous clinical settings. Ther Drug Monit.2005;27: 785-792. (Pubitemid 44391736)
11. Maloney DG, Liles TM, Czerwinski DK, et al. PhaseI clinical trial using escalating single-dose infusionof chimeric anti-CD20 monoclonal antibody(IDEC-C2B8) in patients with recurrent B-celllymphoma. Blood. 1994;84: 2457-2466. (Pubitemid 24317376)
12. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of achimeric anti-CD20 monoclonal antibody (IDECC2B8,rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol.1998;9: 527-534. (Pubitemid 28270641)
13. Tobinai K, Igarashi T, Itoh K, et al. Japanesemulticenter phase II and pharmacokinetic studyof rituximab in relapsed or refractory patientswith aggressive B-cell lymphoma. Ann Oncol.2004;15: 821-830. (Pubitemid 38714746)
14. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al.IDEC-C2B8: Results of a phase I multiple-dosetrial in patients with relapsed non-Hodgkin'slymphoma. J Clin Oncol. 1997;15: 3266-3274. (Pubitemid 27419340)
15. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.Rituximab chimeric anti-CD20 monoclonalantibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatmentprogram. J Clin Oncol. 1998;16: 2825-2833. (Pubitemid 28363048)
16. O'Brien SM, Kantarjian H, Thomas DA, et al.Rituximab dose-escalation trial in chroniclymphocytic leukemia. J Clin Oncol. 2001;19: 2165-2170. (Pubitemid 32366970)
17. Hainsworth JD, Litchy S, Barton JH, et al. Singleagentrituximab as first-line and maintenancetreatment for patients with chronic lymphocyticleukemia or small lymphocytic lymphoma: Aphase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21: 1746-1751. (Pubitemid 46638587)
18. Byrd JC, Peterson BL, Morrison VA, et al.Randomized phase 2 study of fludarabine withconcurrent versus sequential treatment withrituximab in symptomatic, untreated patientswith B-cell chronic lymphocytic leukemia: Resultsfrom Cancer and Leukemia Group B 9712 (CALGB9712). Blood. 2003;101: 6-14. (Pubitemid 36025880)
19. Byrd JC, Rai K, Peterson BL, et al. Addition ofrituximab to fludarabine may prolong progressionfreesurvival and overall survival in patientswith previously untreated chronic lymphocyticleukemia: An updated retrospective comparativeanalysis of CALGB 9712 and CALGB 9011. Blood.2005;105: 49-53. (Pubitemid 40053062)
20. Keating MJ, O'Brien S, Albitar M, et al. Earlyresults of a chemoimmunotherapy regimen offludarabine, cyclophosphamide, and rituximab asinitial therapy for chronic lymphocytic leukemia.J Clin Oncol. 2005;23: 4079-4088. (Pubitemid 46211313)
21. Keating MJ, O'Brien S, Tam C, Lerner S, KantarjianH. Salvage therapy following failure or relapse afterFCR chemo-immunotherapy as initial treatmentfor chronic lymphocytic leukemia (CLL). J ClinOncol. 2007;25(Suppl. 18): Abstract 7009.
22. Hallek M, Fischer K, Fingerle-Rowson G, etal. Addition of rituximab to fludarabine andcyclophosphamide in patients with chroniclymphocytic leukaemia: A randomised, open-label,phase 3 trial. Lancet. 2010;376: 1164-1174.
23. Kay NE, Geyer SM, Call TG, et al. Combinationchemoimmunotherapy with pentostatin,cyclophosphamide, and rituximab showssignificant clinical activity with low accompanyingtoxicity in previously untreated B chroniclymphocytic leukemia. Blood. 2007;109: 405-411. (Pubitemid 46105933)
24. Foon KA, Boyiadzis M, Land SR, et al.Chemoimmunotherapy with low-dose fludarabineand cyclophosphamide and high dose rituximabin previously untreated patients with chroniclymphocytic leukemia. J Clin Oncol. 2009;27: 498-503.
25. Lamanna N, Jurcic JG, Noy A, et al. Sequentialtherapy with fludarabine, high-dosecyclophosphamide, and rituximab in previouslyuntreated patients with chronic lymphocyticleukemia produces high-quality responses: Molecular remissions predict for durable completeresponses. J Clin Oncol. 2009;27: 491-497.
26. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: A new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J ClinOncol. 2009;27: 4578-4584.
27. Faderl S, Wierda W, O'Brien S, Ferrajoli A, LernerS, Keating MJ. Fludarabine, cyclophosphamide,mitoxantrone plus rituximab (FCM-R) in frontlineCLL <70 years Leuk Res. 2010, 34, 284-288.
28. Fischer K, Stilgenbauer S, Schweighofer CD, et al.Bendamustine in combination with rituximab (BR)for patients with relapsed chronic lymphocyticleukemia (CLL): A multicentre phase II trial of theGerman CLL Study Group (GCLLSG). AmericanSociety of Hematology Annual Meeting, December6-9, 2008, San Fransisco, CA. Abstract 330.
29. Parikh SA, O'Brien S, Ferrajoli A. Frontlinecombined chemoimmunotherapy withfludarabine, cyclophosphamide, alemtuzumab andrituximab (CFAR) in high-risk chronic lymphocyticleukemia. American Society of Hematology Annual Meeting December 5-8, 2009, New Orleans, LA.Abstract 208.
30. Di Gaetano N, Xiao Y, Erba E, et al. Synergismbetween fludarabine and rituximab revealedin a follicular lymphoma cell line resistant tothe cytotoxic activity of either drug alone. BrJ Haematol. 2001;114: 800-809. (Pubitemid 32953735)
31. Alas S, Bonavida B, Emmanouilides C. Potentiationof fludarabine cytotoxicity on non-Hodgkin'slymphoma by pentoxifylline and rituximab.Anticancer Res. 2000;20: 2961-2966.
32. Schulz H, Klein SK, Rehwald U, et al. Phase 2study of a combined immunochemotherapy usingrituximab and fludarabine in patients with chroniclymphocytic leukemia. Blood. 2002;100: 3115-3120. (Pubitemid 35217057)
33. Byrd JC, Murphy T, Howard RS, et al. Rituximabusing a thrice weekly dosing schedule in B-cellchronic lymphocytic leukemia and smalllymphocytic lymphoma demonstrates clinicalactivity and acceptable toxicity. J Clin Oncol.2001;19: 2153-2164. (Pubitemid 32366969)
34. Byrd JC, Gribben JG, Peterson BL, et al. Select highriskgenetic features predict earlier progressionfollowing chemoimmunotherapy with fludarabineand rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol.2006;24: 437-443. (Pubitemid 46655595)
35. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared withfludarabine for patients with previously untreatedchronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25: 793-798. (Pubitemid 350002879)
36. Eichhorst BF, Busch R, Hopfinger G, et al.Fludarabine plus cyclophosphamide versusfludarabine alone in first-line therapy of youngerpatients with chronic lymphocytic leukemia.Blood. 2006;107: 885-891. (Pubitemid 43156283)
37. Tam CS, O'Brien S, Wierda W, et al. Long-termresults of the fludarabine, cyclophosphamide, andrituximab regimen as initial therapy of chroniclymphocytic leukemia. Blood. 2008;112: 975-980.
38. Lin KI, Tam CS, Keating MJ, et al. Relevance ofthe immunoglobulin VH somatic mutation statusin patients with chronic lymphocytic leukemiatreated with fludarabine, cyclophosphamide, andrituximab (FCR) or related chemoimmunotherapyregimens. Blood. 2009;113: 3168-3171.
39. Constantine ST, Wierda GW, O'Brien S, et al. Life after fludarabine, cyclophosphamide, & rituximab (FCR) -the clinical outcome ofpatients with chronic lymphocytic leukemiawho receive salvage treatment after frontlineFCR. American Society of Hematology Annual Meeting, December 6-9, 2008, San Fransisco, CA.Abstract 2090.
40. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expressionis dependent on the genetic subtype: A study ofquantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol.2008;141: 36-40. (Pubitemid 351347535)
41. Dohner H, Stilgenbauer S, Benner A, et al. Genomicaberrations and survival in chronic lymphocyticleukemia. N Engl J Med. 2000;343: 1910-1916.
42. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin,cyclophosphamide, and rituximab regimen inolder patients with chronic lymphocytic leukemia.Cancer. 2007;109: 2291-2298. (Pubitemid 46801560)
43. Kay NE, Wu W, Kabat B, et al. Pentostatin andrituximab therapy for previously untreatedpatients with B-cell chronic lymphocytic leukemia.Cancer. 2010;116: 2180-2187.
44. Reynolds CM, Di Bella N, Lyons RM, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocyticleukemia. American Society of HematologyAnnual Meeting, December 6-9, 2008, San Fransisco, CA. Abstract 327.
45. Fischer KPC, Stilgenbauer S, Busch R, et al.Bendamustine combined with rituximab (BR) infirst-line therapy of advanced CLL: A multicenterphase II trial of the German CLL Study Group(GCLLSG). American Society of HematologyAnnual Meeting, December 5-8, 2009, NewOrleans, LA. Abstract 205.
46. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloidleukemia following fludarabine combinationchemotherapy. Leukemia. 2010;24: 2056-2062.
47. Wierda W, O'Brien S, Wen S, et al.Chemoimmunotherapy with fludarabine,cyclophosphamide, and rituximab for relapsed andrefractory chronic lymphocytic leukemia. J ClinOncol. 2005;23: 4070-4078. (Pubitemid 46211312)
48. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2study of lumiliximab combined with fludarabine,cyclophosphamide, and rituximab in patientswith relapsed or refractory chronic lymphocyticleukemia. Blood. 2010;115: 489-495.
49. Lamanna N, Kalaycio M, Maslak P, et al.Pentostatin, cyclophosphamide, and rituximab isan active, well-tolerated regimen for patients withpreviously treated chronic lymphocytic leukemia. JClin Oncol. 2006;24: 1575-1581. (Pubitemid 46638781)
50. Bertazzoni P, Rabascio C, Gigli F, et al. Rituximab and subcutaneous cladribine in chronic lymphocyticleukemia for newly diagnosed and relapsed patients.Leuk Lymphoma. 2010;51: 1485-1493.
51. Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Blonski JZ. Rituximab plus cladribinewith or without cyclophosphamide in patientswith relapsed or refractory chronic lymphocyticleukemia. Eur J Haematol. 2007;79: 107-113. (Pubitemid 47063264)
52. Badoux Xavier C. MK, Susan O'Brien, et al.Chemoimmunotherapy with cyclophosphomide,fludarabine, alemtuzumab and rituximab (CFAR)is effective in relapsed patients with chroniclymphocytic leukemia (CLL). American Society ofHematology Annual Meeting, December 5-8, 2009,New Orleans, LA. Abstract 3431.
53. Tsimberidou AM, Wierda WG, Plunkett W, etal. Phase I-II study of oxaliplatin, fludarabine,cytarabine, and rituximab combination therapy inpatients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J ClinOncol. 2008;26: 196-203.
54. Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolonefor the treatment of chronic lymphocytic leukemia.Leukemia. 2009;23: 1779-1789.
55. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L,Kipps TJ. Rituximab in combination with highdosemethylprednisolone for the treatmentof fludarabine refractory high-risk chroniclymphocytic leukemia. Leukemia. 2008;22: 2048-2053.
56. Woyach JA, Lin TS, Lucas MS, et al. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocyticlymphoma. Leukemia. 2009;23: 912-918.
57. Zent CS, Call TG, Shanafelt TD, et al. Earlytreatment of high-risk chronic lymphocyticleukemia with alemtuzumab and rituximab.Cancer. 2008;113: 2110-2118.
58. Faderl S, Ferrajoli A, Wierda W, O'Brien S, LernerS, Keating MJ. Alemtuzumab by continuousintravenous infusion followed by subcutaneousinjection plus rituximab in the treatment ofpatients with chronic lymphocytic leukemiarecurrence. Cancer. 2010;116: 2360-2365.
59. Faderl S, Thomas DA, O'Brien S, et al. Experiencewith alemtuzumab plus rituximab in patients withrelapsed and refractory lymphoid malignancies.Blood. 2003;101: 3413-3415. (Pubitemid 36857922)
60. Ferrajoli A. Incorporating the use of GM-CSF in thetreatment of chronic lymphocytic leukemia. LeukLymphoma. 2009;50: 514-516.
61. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, etal. Immunomodulatory drugs stimulate naturalkiller-cell function, alter cytokine production bydendritic cells, and inhibit angiogenesis enhancingthe anti-tumour activity of rituximab in vivo. Br JHaematol. 2008;140: 36-45. (Pubitemid 350233246)
62. James DF, Brown JR, Werner L, et al. Lenalidomideand rituximab for the initial treatment of chroniclymphocytic leukemia: Report of an ongoing study.J Clin Oncol. 2010;28(Suppl. 15). Abstract 6583.
63. Ferrajoli AXCB, O'Brien S, Wierda WG et al.Combination therapy with lenalidomide andrituximab in patients with relapsed chroniclymphocytic leukemia (CLL). American Society ofHematology Annual Meeting, December 5-8, 2009,New Orleans, LA. Abstract 206.
64. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomideinduces complete and partial remissions in patientswith relapsed and refractory chronic lymphocyticleukemia. Blood. 2008;111: 5291-5297.
65. Del Poeta G, Del Principe MI, Consalvo MA, et al.The addition of rituximab to fludarabine improvesclinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.Cancer. 2005;104: 2743-2752. (Pubitemid 41798284)
66. Del Poeta G, Del Principe MI, Buccisano F, et al.Consolidation and maintenance immunotherapywith rituximab improve clinical outcome inpatients with B-cell chronic lymphocytic leukemia.Cancer. 2008;112: 119-128.
67. Carson KR, Evens AM, Richey EA, et al. Progressivemultifocal leukoencephalopathy after rituximabtherapy in HIV-negative patients: A report of 57cases from the Research on Adverse Drug Eventsand Reports project. Blood. 2009;113: 4834-4840.
68. D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I.Progressive multifocal leukoencephalopathy inchronic lymphocytic leukemia: A report of threecases and review of the literature. Clin LymphomaMyeloma Leukemia. 2010;10: E1-9.
69. Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in a surface antigennegativepatient with B-cell chronic lymphocyticleukaemia after rituximab therapy. Leukemia. 2005;19: 1840-1841. (Pubitemid 41486166)
70. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20monoclonal antibodies with potent cytolyticactivity against non-Hodgkin lymphomas. Blood.2004;104: 1793-1800. (Pubitemid 39202289)
71. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, etal. Chemoimmunotherapy with ofatumumab,fludarabine, and cyclophosphamide (O-FC)in previously untreated patients with chroniclymphocytic leukemia (CLL). J Clin Oncol.2010;28(Suppl. 15). Abstract 6520.
72. Patz M, Forcob N, Müller B, et al. Depletion of chronic lymphocytic leukemia cells from whole blood samples mediated by the anti-CD20antibodies rituximab and GA101 [abstract].American Society of Hematology Annual Meeting December 5-8, 2009, New Orleans, LA.Abstract 2365.
73. Morschhauser FGC, Lamy T, Milpied NJ, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. American Society of Hematology Annual Meeting December 5-8, 2009, New Orleans, LA.Abstract 884.